NCT04446429View on ClinicalTrials.gov

Anti-Androgen Treatment for COVID-19

NACompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

December 24, 2020

Study Completion Date

January 21, 2021

Conditions
COVID-19SARS-CoV2Androgenetic AlopeciaProstate CancerBenign Prostatic HyperplasiaSARS (Severe Acute Respiratory Syndrome)
Interventions
DRUG

Proxalutamide

200 mg q.d.

OTHER

Standard of Care

Standard of care as determined by the PI

Trial Locations (1)

70390-150

Corpometria Institute, Brasília

Sponsors
All Listed Sponsors
lead

Applied Biology, Inc.

INDUSTRY